. Author manuscript; available in PMC: 2017 Aug 1.

Published in final edited form as: Transplantation. 2017 Feb;101(2):360–367. doi: 10.1097/TP.0000000000001455

Table 4.

TTV load in relation to immunosuppression and kidney function

Variables	TTV copies/mL, median (IQR)		p-value
Variables	Yes	No	p-value
Initial immunosuppression
Induction therapy	3.1x10⁵ (2.6x10⁴-3.7x10⁶)	1.4x10⁵ (9.8x10³-1.0x10⁶)	<0.001
Tacrolimus	2.9x10⁵ (2.2x10⁴-3.1x10⁶)	1.4x10⁵ (1.3x10⁴-9.5x10⁵)	0.002
Cyclosporine	1.3x10⁵ (7.7x10³-6.2x10⁵)	3.0x10⁵ (2.2x10⁴-4.4x10⁶)	<0.001
mTOR inhibitor	3.9x10⁴ (3.6x10³-5.7x10⁵)	2.4x10⁵ (2.0x10⁴-1.9x10⁶)	0.03
Belatacept	9.5x10⁶ (2.1x10⁶-6.4x10⁷)	2.1x10⁵ (1.8x10⁴-1.6x10⁶)	<0.001
Mycophenolic acid	2.6x10⁵ (1.9x10⁴-2.5x10⁶)	1.6x10⁵ (8.2x10³-8.7x10⁵)	0.39
Immunosuppression at screening
Triple immunosuppression	2.8x10⁵ (2.2x10⁴-2.6x10⁶)	1.2x10⁵ (1.2x10⁴-7.4x10⁵)	0.001
Steroid	2.7x10⁵ (2.1x10⁴-2.4x10⁶)	1.3x10⁵ (1.4x10⁴-6.0x10⁵)	0.01
Tacrolimus	2.8x10⁵ (2.3x10⁴-2.2x10⁶)	1.4x10⁵ (1.0x10⁴-1.2x10⁶)	0.01
Tacrolimus through level >median^a	2.8x10⁵ (2.2x10⁴-1.7x10⁶)	2.8x10⁵ (2.2x10⁴-2.2x10⁶)	0.20
Cyclosporine	1.0x10⁵ (7.0x10³-5.4x10⁵)	2.9x10⁵ (2.2x10⁴-2.6x10⁶)	<0.001
Cyclosporine through level >median^a	9.5x10⁴ (7.5x10³-8.3x10⁵)	1.3x10⁵ (6.7x10³-5.2x10⁵)	0.46
mTOR inhibitor	6.4x10⁴ (6.4x10³-2.8x10⁶)	2.4x10⁵ (2.1x10⁴-1.9x10⁶)	0.24
Belatacept	1.0x10⁷ (3.1x10⁶-2.6x10⁸)	2.1x10⁵ (1.9x10⁴-1.6x10⁶)	<0.001
Antimetabolite	2.4x10⁵ (2.1x10⁴-2.2x10⁶)	1.0x10⁵ (3.9x10³-7.7x10⁵)	0.03
Kidney function at screening
Protein-creatinine ratio >median^a	2.1x10⁵ (1.8x10⁴-1.7x10⁶)	2.5x10⁵ (2.3x10⁴-1.9x10⁶)	0.40
eGFR >median^a	2.7x10⁵ (3.7x10⁴-2.4x10⁶)	1.6x10⁵ (7.9x10³-1.9x10⁶)	0.003

TTV, Torque Teno virus; IQR, interquartile range; mTOR, mechanistic target of rapamycin; eGFR, estimated glomerular filtration rate.

For continuous data the median was selected as cut off value to define positivity (tacrolimus level >6 ng/mL, cyclosporine >67 ng/mL, protein-creatinine ratio ratio >154 mg/g, eGFR >42 mL/minute/1.73 m²).